Lv1
80 积分 2023-11-08 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Points to consider for the next-generation-sequencing-based detection of copy-number abnormalities (CNAs) and balanced chromosomal rearrangements in neoplastic disorders: A statement of the American College of Medical Genetics and Genomics (ACMG)
4个月前
已完结
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
4个月前
已完结
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
4个月前
已完结
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
4个月前
已完结
[Expert consensus on homologous recombination repair gene testing and variant interpretation in prostate cancer]
5个月前
已完结
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
6个月前
已完结
Uncovering Demographic Bias in Natural Language Processing Tools for Radiology
7个月前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
7个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
7个月前
已完结
皖公网安备34019202002308
